Chahra Louafi is Senior Investment Director and Head of the Biotherapies and Rare Diseases Fund of Bpifrance (formerly CDC Entreprises). Before joining CDC Entreprises in 2001, Chahra Louafi was in charge of project development and company creation for a private incubator that specialised in biotechnologies. She is Chairman of the Supervisory Board of Inserm Transfert Initiative and member of the Supervisory Board of Cap Decisif Management. She is an investor and a board member of the following private and public companies: DBV Technologies, Eyevensys, Sensorion, MedDay Pharmaceuticals, Pixium Vision, Lysogene, Annapurna Therapeutics, BrainEver, Enyo Pharma, Gecko Biomedical; GMP-Orphan, Sparingvision and Therachon. Ms. Louafi holds a Master in Technology and Innovation Management from Paris Dauphine University, a Master in Corporate Finance from Paris X Nanterre University and MSC in Microbiology and Enzymatic Engineering from Institut National Agronomique Paris-Grignon. She was recently awarded the title of Chevalier de l'Ordre National du Mérite (Knight in the National Order of Merit) for her public service and contributions to the French biotech sector.

Biotherapies